Clinical Trials Logo

Pruritus clinical trials

View clinical trials related to Pruritus.

Filter by:

NCT ID: NCT03751111 Completed - Chronic Pruritus Clinical Trials

Treatment of Chronic Itch in Patients Under Arsenic Exposure With Sublingual Naloxone

Start date: February 13, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of sublingual naloxone in the treatment of chronic itch in patients under arsenic exposure.

NCT ID: NCT03701971 Completed - Pruritus Clinical Trials

Study Evaluating the Benefit of Music Therapy on Pruritus in Patients With Pruritic Dermatitis

PRURI-MUSIC
Start date: November 8, 2018
Phase: N/A
Study type: Interventional

Many clinical studies have shown the benefit of music therapy in various pathologies, including pain, and it is now established that the latter has a complementary therapeutic interest. Its most frequently identified indications are the fight against acute or chronic pains, the reduction of anxiety, depression and stress, as well as memory disorders such as Alzheimer's disease. The main modes of action of music therapy involve sensory, cognitive, psychological and behavioral processes that are also found in pruritus. Pruritus is defined as "an uncomfortable sensation causing the need to scratch. It has similarities with pain but also differences: relief by heat / cold, scratching / withdrawal behavior, localization on the skin, semi-mucous / ubiquitous ... etc. The pathophysiology also has similarities, pruritus is born at the dermal-epidermal junction at the level of specific cutaneous receptors then follows the classical pathways through a 1st neuron, then the dorsal horn of the spinal cord and a second neuron. At the cerebral level, there is no single center of pruritus but several motor and sensory areas involved. The similarities suggest that music therapy may have an interest in the management of chronic pruritus, especially since classical treatments (antihistamines, topical corticosteroids) have only partial efficacy in some dermatoses

NCT ID: NCT03688490 Completed - Clinical trials for Myeloproliferative Disorder

Clinical Characteristics of Aquagenic Pruritus in Patients With Myeloproliferative Neoplasms

PASYMPLE
Start date: July 17, 2013
Phase:
Study type: Observational

Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms. Prospective work based on the distribution of a dedicated questionnaire.

NCT ID: NCT03677401 Completed - Pruritus Clinical Trials

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Start date: August 29, 2018
Phase: Phase 3
Study type: Interventional

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

NCT ID: NCT03673878 Completed - Brain Tumor Clinical Trials

Prevalence of a Localized or Diffuse Pruritus in a Population With One or Several, Primitive or Secondary, Brain Tumor(s)

PRURI-C
Start date: June 29, 2020
Phase:
Study type: Observational

The association between the presence of pruritus, especially centrofacial, and the presence of a brain tumor is a widespread notion in the medical community but based on a single publication by Andreev et al. in the British Journal of Dermatology published in 1975. No other study has studied this association with a rigorous methodology. The aim of this study is to evaluate the prevalence of pruritus in patients with one or more primary or secondary brain tumor(s), benign(s) or malignant(s).

NCT ID: NCT03636269 Completed - Uremic Pruritus Clinical Trials

CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

KALM-2
Start date: July 17, 2018
Phase: Phase 3
Study type: Interventional

This is a multicenter, international study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week randomized, double-blind, placebo-controlled Phase and a 52-week Open-label Extension Phase.

NCT ID: NCT03630107 Completed - Clinical trials for Pruritus of the Scalp

In-Use Test of a Cosmetic Product in Subjects With Chronically Itchy Scalp

Start date: February 15, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the tolerance of the Shampoo (WO 5101) on the scalp by a dermatologist and by the subjects themselves after four weeks of regular product use. Additional objective of this clinical in-use study was to evaluate the cosmetic features and the acceptance of the product by means of a questionnaire at the end of the 4-week treatment period.

NCT ID: NCT03617536 Completed - Clinical trials for Chronic Kidney Diseases

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

Start date: July 5, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of 3 dose levels of oral CR845 compared to placebo in reducing the intensity of itch in chronic kidney disease (CKD) patients with moderate-to-severe pruritus. This study will consist of a Screening Period, a 7-day Run-in Period, a 12 week Treatment Period, and a Follow-up Visit (approximately 7 days after the last dose of study drug).

NCT ID: NCT03610386 Completed - Atopic Dermatitis Clinical Trials

Effects of an Anti-TRPM8 in the Atopic Dermatitis Pruritus

DA-TRPM8
Start date: November 21, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to analyse the effect of the menthoxypropanediol, a derivative of menthol, on the pruritus of atopic dermatitis (ex vivo study).

NCT ID: NCT03576235 Completed - Uremic Pruritus Clinical Trials

Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients

SNUG
Start date: May 1, 2018
Phase: N/A
Study type: Interventional

In this study (SNUG trial), the investigators aim to investigate the anti-pruritic effect of PG102P in comparison with placebo in 80 patients undergoing HD.